Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evangelos Terpos

Showing results (1-10 of 717) with videos related to

Pageof 72
Sort By:
Critical Reviews in Oncology/Hematology|March 1, 2011
Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuumEvangelos Terpos
Leukemia Research|July 11, 2008
Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone diseaseEvangelos Terpos
Leukemia Research|January 16, 2010
Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone diseaseEvangelos Terpos
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2017
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016Evangelos Terpos,
Cancer Treatment Reviews|May 9, 2006
Biochemical markers of bone metabolism in multiple myelomaEvangelos Terpos
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonate anticancer activity in multiple myelomaEvangelos Terpos
Clinical Lymphoma, Myeloma & Leukemia|March 27, 2018
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017Evangelos Terpos,
Leukemia Research|November 25, 2010
The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patientsEvangelos Terpos
Idrugs : the Investigational Drugs Journal|December 2, 2006
What's new in bone research--anabolics, tissue repair, therapeutic strategies and moreEvangelos Terpos
Leukemia Research|October 5, 2007
Have myeloma cells osteoclast-like activity? Implications into the pathogenesis of myeloma bone diseaseEvangelos Terpos
Pageof 72

Showing results (1-10 of 717) with videos related to

Sort By:
Pageof 72
Critical Reviews in Oncology/Hematology|March 1, 2011
Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuumEvangelos Terpos
Leukemia Research|July 11, 2008
Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone diseaseEvangelos Terpos
Leukemia Research|January 16, 2010
Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone diseaseEvangelos Terpos
Clinical Lymphoma, Myeloma & Leukemia|May 3, 2017
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016Evangelos Terpos,
Cancer Treatment Reviews|May 9, 2006
Biochemical markers of bone metabolism in multiple myelomaEvangelos Terpos
Anti-Cancer Agents in Medicinal Chemistry|August 26, 2011
Bisphosphonate anticancer activity in multiple myelomaEvangelos Terpos
Clinical Lymphoma, Myeloma & Leukemia|March 27, 2018
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017Evangelos Terpos,
Leukemia Research|November 25, 2010
The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patientsEvangelos Terpos
Idrugs : the Investigational Drugs Journal|December 2, 2006
What's new in bone research--anabolics, tissue repair, therapeutic strategies and moreEvangelos Terpos
Leukemia Research|October 5, 2007
Have myeloma cells osteoclast-like activity? Implications into the pathogenesis of myeloma bone diseaseEvangelos Terpos
Pageof 72